Evidence map›Paper›PMID 33096336›Full record

ArticleTranslational oncology2021

Dynamic differences between DNA damage repair responses in primary tumors and cell lines.

Collin Gilbreath, Shihong Ma, Lan Yu, Rajni Sonavane, Carlos M Roggero, Anvita Devineni, Ryan Mauck, Neil B Desai, Aditya Bagrodia, Ralf Kittler and 2 more

Open access · goldAbstract read
In one paragraph

Article in Translational oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Collin GilbreathDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Shihong MaDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Lan YuDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Rajni SonavaneDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Carlos M RoggeroDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Anvita DevineniDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Ryan MauckDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Neil B DesaiDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Aditya BagrodiaDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Ralf KittlerEugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Ganesh V RajDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: Ganesh.Raj@utsouthwestern.edu.
Yi YinDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: Yi.Yin@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · USSouthwestern Medical Center · US

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MELANIE H. COBB · 2010 to 2026
$53.7M
Development of small molecules for ERG ablation in prostate cancerR01CA200787 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI KITTLER, RALF · 2016 to 2020
$1.8M
NCI NIH HHS P30 CA142543NCI NIH HHS R01 CA200787
6 · The paper itself

Abstract

The study of DNA damage repair response (DDR) in prostate cancer is restricted by the limited number of prostate cancer cell lines and lack of surrogates for heterogeneity in clinical samples. Here, we sought to leverage our experience with patient derived explants (PDEs) cultured ex vivo to study dynamics of DDR in primary tumors following application of clinically relevant doses of ionizing radiation (IR) to tumor cells in their native 3-dimensional microenvironment. We compared DDR dynamics between prostate cancer cell lines, PDEs and xenograft derived explants (XDEs) following treatment with IR (2Gy) either alone or in combination with pharmacological modulators of DDR. We have shown that following treatment with 2Gy, DDR can be consistently detected in PDEs from multiple solid tumors, including prostate, kidney, testes, lung and breast, as evidenced by γ-H2AX, 53BP1, phospho-ATM and phospho-DNA-PKcs foci. By examining kinetics of resolution of IR-induced foci, we have shown that DDR in prostate PDEs (complete resolution in 8 h) is much faster than in prostate cancer cell lines (<50% resolution in 8 h). The transcriptional profile of DDR genes following 2Gy IR appears to be distinct between PDEs and cell lines. Pre-treatment with drugs targeting DDR pathways differentially alter the kinetics of DDR in the PDEs and cell lines, as evidenced by altered kinetics of foci resolution. This study highlights the utility of PDEs as a robust model system for short-term evaluation of DDR in primary solid tumors in clinically relevant microenvironment.

Indexed as

DNA damage response, DNA repairEx vivo culturepatient-derived explantradiation resistanceTumor microenvironment

Identifiers

PMID33096336
PMCPMC7576517
OpenAlexW3094247229

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.